Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study
Annals of the Rheumatic DiseasesPublished 23 November 2003Open access
Niki Tsifetaki, G Kitsos, C A Paschides, Y Alamanos, V Eftaxias, P V Voulgari
Citations143
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
10 mg of pilocarpine daily given to patients with primary Sjögren’s syndrome for 12 weeks had a beneficial effect on subjective eye symptoms, as evaluated by improvement >55 mm on a VAS.
Abstract
10 mg of pilocarpine daily given to patients with SS for 12 weeks had a beneficial effect on subjective eye symptoms, as evaluated by improvement >55 mm on a VAS. Additionally, an improvement of rose bengal staining was noted, but an increase in tear production, as measured by the Schirmer-I test, was not substantiated.
Keywords
Medicine
Annals of the Rheumatic DiseasesClassification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
5,259 Citations2002Claudio Vitali, S Bombardieri +11 more
These classification criteria for Sjögren's syndrome have been re-examined by consensus group members, who have introduced some modifications, more clearly defined the rules for classifying patients with primary or secondary SS, and provided more precise exclusion criteria.
Archives of Internal MedicinePilocarpine Tablets for the Treatment of Dry Mouth and Dry Eye Symptoms in Patients With Sjögren Syndrome<subtitle>A Randomized, Placebo-Controlled, Fixed-Dose, Multicenter Trial</subtitle>
441 Citations1999Frederick B. Vivino
Administration of 5-mg pilocarpine tablets 4 times daily (20 mg/d) was well tolerated and produced significant improvement in symptoms of dry mouth and dry eyes and other xeroses in patients with SS.
Clinical Immunology and ImmunopathologySjöc;gren's Syndrome: Autoimmune Epithelitis
436 Citations1994Haralampos Μ. Moutsopoulos
Based on the sequential application of the validated European classification criteria for SS, a practical algorithm for diagnosis is presented and progress in the understanding of the broad clinicopathological spectrum of the entity remains largely empirical and symptomatic.
Archives of OphthalmologyAnalysis of Topical Cyclosporine Treatment of Patients With Dry Eye Syndrome<subtitle>Effect on Conjunctival Lymphocytes</subtitle>
333 Citations2000Kathleen S. Kunert
Scandinavian Journal of RheumatologyFasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review
286 Citations2001F. Müller
Arthritis & RheumatismA double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca
279 Citations2002Dianne Petrone, John J. Condemi +4 more
Treatment with cevimeline at a dosage of 30 mg 3 times daily resulted in substantive improvement by increasing the rate of saliva and tear flow in patients with Sjögren's syndrome, as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness.
Current Opinion in RheumatologyUpdate in Sjögren syndrome
249 Citations2000Robert I. Fox, Michael E. Stern +1 more
Even in SS patients with marked sicca symptoms, minor salivary gland biopsy shows that almost 50% of glandular cells are still detected on biopsy, implying the importance of immune factors such as cytokines and autoantibodies in decreasing neuro-secretory circuits and induction of glandsular dysfunction.
Arthritis & RheumatismInhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome
239 Citations2000Sally A. Waterman, Tom P. Gordon +1 more
DrugsOral Pilocarpine
178 Citations1995Lynda R. Wiseman, Diana Faulds
Oral pilocarpine is an effective agent for the treatment of xerostomia, increasing salivary flow and reducing symptom severity to a significantly greater extent than placebo.
American Journal of OphthalmologyEfficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome
159 Citations2001Mini Balaram, Debra A. Schaumberg +1 more
There is both a reduced dependency on artificial lubricants and relief of symptoms of dry eye after punctal plugs, however, spontaneous plug loss occurs in a substantial minority of patients.
Best Practice & Research Clinical RheumatologySjögren's syndrome: autoimmune epithelitis
140 Citations2000Menelaos N. Manoussakis, Haralampos Μ. Moutsopoulos
Etithelial cells seem to exert a regenerative effort since they express trefoil proteins (pS2), which give epithelial cells a significant role in the pathophysiology of the syndrome but the exact events which drive the immune system towards an autoimmune reaction remain obscure.
PubMedMethotrexate in primary Sjögren's syndrome.
133 Citations1997Fotini N. Skopouli, Peter Jagiello +2 more
The American Journal of MedicineTreatment of primary Sjögren's syndrome with hydroxychloroquine
127 Citations1988Robert I. Fox, Edward K. L. Chan +4 more
It is suggested that hydroxychloroquine modulates lymphoproliferation in patients with Sjögren's syndrome and may prevent progression to extraglandular sites of neoplastic transformation.
OphthalmologyA randomized, placebo-controlled trial of topical cyclosporin a in steroid-dependent atopic keratoconjunctivitis,
122 Citations1998Melanie Hingorani
Topical CsA is an effective and safe steroid-sparing agent in atopic keratoconjunctivitis and, despite difficulties in patient tolerance, also improves symptoms and signs.
Journal of Interferon & Cytokine ResearchTreatment of Primary Sjogren's Syndrome with Low-Dose Natural Human Interferon-alpha Administered by the Oral Mucosal Route: A Phase II Clinical Trial
120 Citations1999Jonathan A. Ship, Philip C. Fox +4 more
This randomized, double-blinded clinical trial demonstrated that nHuIFN-alpha at a dose of 150 IU administered TID by oral lozenge significantly improved stimulated whole saliva output compared to placebo after 12 weeks of treatment.
PubMedA double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.
109 Citations1998Elizabeth Price, S. Rigby +2 more
This trial suggests that low dose AZA does not have a role as a disease modifying agent in SS.
Medical Entomology and ZoologySjogren's Syndrome: Clinical and Immunological Aspects
95 Citations1987Norman Talal, Haralampos Μ. Moutsopoulos +1 more
This chapter discusses the diagnosis and treatment of Sjogren's Syndrome, as well as the relationship to other Autoimmune Diseases, and the relationship between Anti-RO(SS-A) Precipitin Antibody Positive Sjosogren’s Syndrome and Anti- RO(SS)-A PrecipItin AntIBody Positive Lupus Erythematosus.
Scandinavian Journal of RheumatologySjögren's syndrome: mechanisms ofpathogenesis involve interaction of immune and neurosecretory systems
91 Citations2002Robert L. Fox, Michael E. Stern
Patients with Sjögren's syndrome have focal lymphocytic infiltrates and partial destruction of glandular secretory units, and the ability to modulate immune response and stimulate residual glandular elements provides new therapeutic opportunities.
Annals of the Rheumatic DiseasesCyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.
85 Citations1986Alexandros A. Drosos, Fotini N. Skopouli +3 more
The histopathological lesion of patients treated with CyA remained unchanged in most of the patients, while in the placebo treated group the lesion deteriorated, and the only clinical side effect observed in the CyA treated group was hypertrichosis.
Oral Surgery Oral Medicine Oral PathologyEffects of pilocarpine on salivary flow in patients with Sjo¨gren's syndrome
65 Citations1991N.L. Rhodus, M. Schuh
The results of this study support the use of pilocarpine to increase salivary flow in patients with SS.
PubMedSjögren's syndrome: a critical review of clinical management.
61 Citations1999Mary Bell, Ali Askari +6 more
Dental, gynecological, and ophthalmological perspectives on diagnosis and management are discussed; the primary practitioner has the opportunity to play both a coordinating role and a direct role in early diagnosis and treatment.
Scandinavian Journal of RheumatologySjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems
46 Citations2002Robert I. Fox, Michael E. Stern
Patients with Sjo¨gren's syndrome have focal lymphocytic infiltrates and partial destruction of glandular secretory units, and the ability to modulate immune response and stimulate residual glandular elements provides new therapeutic opportunities.
Oral DiseasesOral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome
44 Citations1997NL Rhodus
A significant increase in labial Salivary gland flow as well as whole salivary flow as stimulated by pilocarpine HCl in Sjögren's syndrome patients is indicated.
European Journal of PharmacologyLong-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs
42 Citations1997Hiroaki Masunaga, Hiromi Ogawa +4 more
Results indicate that SNI-2011 may be useful in the treatment of xerostomia because of its long-lasting sialogogic action and effective plasma levels of SNi-2011 persisted longer than those of pilocarpine.
Scandinavian Journal of RheumatologyThe treatment of Sjögren's syndrome patients with Pilocarpine-tablets
37 Citations2001Frederick B. Vivino
Data from human and animal models suggest that regular use of pilocarpine may not only improve patient quality of life but potentially prevent complications as well.
CytopathologyImpression Cytology In Patients With Keratoconjunctivitis Sicca
35 Citations1993M. V. DE ROJAS, M. T. RODRIGUEZ +2 more
In normal and dry eyes, there is a statistically significant difference both in goblet cell density and grade of metaplasia, between superior and temporal bulbar conjunctiva.
Mediterranean Journal of RheumatologyUpdate on Sjögren’s Syndrome 2018
14 Citations2018Ourania D Argyropoulou, Athanasios G. Tzioufas
An overview of the recent literature on the pathogenesis, clinical features and new therapeutic aspects of Primary Sjögren’s syndrome is provided.
Treatment of Sjögren’s Syndrome
6 Citations1987Norman Talal, Haralampos Μ. Moutsopoulos
Patients with Sjogren’s syndrome should be seen regularly by a rheumatologist, an ophthalmologist, and a dentist for significant functional deterioration, superimposed signs of disease complications or significant changes in the course of the disease.
The biomedical & life sciences collection.Sjogren's syndrome: autoimmune epithelitis
5 Citations2007Haralampos Μ. Moutsopoulos
Evidence-Based Eye CareEfficacy and Tolerability Outcomes after Punctal Occlusion with Silicone Plugs in Dry Eye Syndrome
4 Citations2001Robert C. Kersten